FindTrial
Sign In

A Clinical Study to Evaluate the Efficacy and Safety of CUQ-1720Q on management of cognitive functions in Healthy Subjects.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of CUQ-1720Q on management of cognitive functions in Healthy Subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047728
Enrollment
70
Registered
2022-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: CUQ-1720Q 400 mg: Oral administration 2 doses of CUQ-1720Q 400mg capsule every day for 84 days Control Intervention1: Placebo: Oral administration 2 doses of Placebo 400mg capsule e

Sponsors

Akay Natural Ingredients Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects with normal cognitive function 2.Subjects with a MMSE Score >= 23 3.Diabetes, hypertension and other medical condition patients should be on stable medication for last 3 months. 4.Should not be an any medication for cognition and other neurological disorders. 5.Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening 6.Non-smokers 7.Able to communicate verbally, able to write and speak English and comfortable with using computer 8.Must be willing and able to give informed consent and comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1.Subject with chronic diseases. 2.Subjects who maybe allergic to any of the natural constituents of the Investigational Product. 3.Known HIV or Hepatitis B positive or any other immuno-compromised state 4.Subjects on any other medical or clinical investigation or on any nutrition supplements and dietary regime. 5.Subjects visually or mentally handicapped or having difficulty to communicate 6.History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. 7.Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study.

Design outcomes

Primary

MeasureTime frame
change in Neuro cognitive batteryTimepoint: Day 0, Day 42, Day 84—

Secondary

MeasureTime frame
Changes in BiomarkersTimepoint: Day 0, Day 84;Over all SfetyTimepoint: Day 0, Day 42, Day 84—

Countries

India

Contacts

Public ContactJestin V Thomas

Leads Clinical Research and Bioservices Pvt. Ltd

jestin.leadsclinbio@gmail.com09845125293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026